AbbVie seeks EMA marketing authorisation for preventive migraine therapy
The MAA is based on data from two Phase III trials of atogepant in adult patients with episodic and chronic…

The MAA is based on data from two Phase III trials of atogepant in adult patients with episodic and chronic…
The latest development is based on findings from the global Phase III OlympiA trial of Lynparza.
The company has established a non-commercial Global Health Unit to meet the goals.
The EC approval is based on positive findings from the Phase II GEOMETRY mono-1 clinical trial of Tabrecta.
The latest approval is based on findings from seven trials of the vaccine in infants, children and adolescents.
In a Phase III trial, treatment with Voxzogo offered transient declines in blood pressure.
Further trials for pediatric and heart failure patients are currently ongoing.
ByIn a Phase I PK bridging study, Hyrimoz 50 mg/mL2 and Hyrimoz HCF had similar safety and immunogenicity.
Thank you for subscribing to Pharmaceutical Technology